Sodium phenylbutyrate
From Wikipedia, the free encyclopedia
 |
|
|
Sodium phenylbutyrate
|
|
| Systematic (IUPAC) name | |
| Sodium 4-phenylbutanoate | |
| Identifiers | |
| CAS number | 1716-12-7 |
| ATC code | A16AX03 |
| PubChem | 15585 |
| Chemical data | |
| Formula | C10H11O2Na |
| Mol. weight | 186.2 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | to phenylacetate |
| Half life | 0.8 hours |
| Excretion | 80% as phenylacetylglutamine |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
not to be used |
| Legal status | |
| Routes | ? |
Sodium phenylbutyrate is an orphan drug, marketed by Ucyclyd Pharma (Hunt Valley, USA) under the trade name Buphenyl® and by Orphan Europe (France) as Ammonaps®. Phenylbutyrate is a prodrug. In the human body it is metabolized by beta-oxidation to phenylacetate. Phenylacetate conjugate with glutamine to phenylacetylglutamine, that is eliminated with the urine.
Sodium phenylbutyrate is also under investigation for the treatment of some sickle-cell disorders (Blood Products Plasma Expanders and Haemostatics) and for use as a potential differentiation-inducing agent in malignant glioma and acute myeloid leukaemia.
[edit] References
1. Batshaw ML, et al. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138 (suppl 1): S46-S55. (PubMed id:11148549) Correction. ibid. 2002; 140: 490.
2. Kang HL, Benzer S, Min KT.; Life extension in Drosophila by feeding a drug.; Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):838-43. Epub 2002 Jan 15.; PMID: 11792861
